Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.

Cancer research - 1 Jun 2002

Liu Lili, Schwartz Stuart, Davis Brian M, Gerson Stanton L

Abstract excerpt

The ability of O(6)-benzylguanine (BG) to inactivate alkyltransferase (AGT) to potentiate the antitumor efficacy of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) is being tested in clinical trials. As of now, there are no examples of acquired resistance to BG+BCNU in the clinical setting. However, we hypothesized that genetically unstable tumors might develop resistance to the combination after repeated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkyl and Aryl Transferases
Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Base Pair Mismatch

Share to Drug Resistance, Multiple

Share to Drug Synergism

Share to Guanine

Share to MutL Protein Homolog 1

Share to O(6)-Methylguanine-DNA Methyltransferase

Source

Identifiers

PMID: 12036916

Genes

AGT
MGMT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.PMID 12036916Read ↗

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.Semantic proximity Read ↗

Clinical Relevance of <i>MGMT</i> in the Treatment of CancerSemantic proximity Read ↗

Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell linesSemantic proximity Read ↗

Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine.Semantic proximity Read ↗

Conserved residue lysine165 is essential for the ability of O6-alkylguanine-DNA alkyltransferase to react with O6-benzylguanine.Semantic proximity Read ↗

S-alkylthiolation of O6-methylguanine-DNA-methyltransferase (MGMT) to sensitize cancer cells to anticancer therapy.Semantic proximity Read ↗

Loss of DNA mismatch repair in acquired resistance to cisplatin.Semantic proximity Read ↗

Temozolomide analog PMX 465 downregulates MGMT expression in HCT116 colorectal carcinoma cellsSemantic proximity Read ↗

Mutations in human O6-alkylguanine-DNA alkyltransferase imparting resistance to O6-benzylguanine.Semantic proximity Read ↗

Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers.Semantic proximity Read ↗

Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effectsSemantic proximity Read ↗

Interaction of mammalian O(6)-alkylguanine-DNA alkyltransferases with O(6)-benzylguanine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.